Breast cancer two-negative and one-positive may require dual-targeted therapy. Breast cancer two-negative and one-positive means that estrogen receptor and progesterone receptor are negative and her-2 gene expression is positive. When the patient has this condition, the effect of choosing endocrine therapy will be poor, and then dual-targeted therapy is usually needed. Breast cancer patients can choose trastuzumab, lapatinib, patuximab and other targeted drugs under the guidance of doctors, which can effectively kill cancer cells, slow down disease progression, reduce tumor recurrence and metastasis, and prolong patients’ survival time. Breast cancer patients with two-negative and one-positive breast cancer should go to the hospital in time and choose the appropriate treatment under the guidance of the doctor.